Abstract: Tumor infiltrating lymphocytes (TILs) are immune cells that have left the bloodstream and migrated into a tumor. TILs have been used in autologous adoptive transfer therapy for the treatment of cancer. Disclosed are methods for rapidly expanding tumor infiltrating lymphocytes using digested tumor cells.

Abstract: Approximately 50% of melanoma patients carry a mutation in the BRAF protein. Targeted therapy with inhibitors of BRAF and the downstream pathway is very effective in these patients, but long-term benefits are limited due to the onset of therapy resistance. Previous studies demonstrated that BRAF inhibitors (BRAFi) positively affect the antitumor immune response mediated by T cells. Disclosed are methods of treating, preventing, inhibiting, reducing, and/or ameliorating a cancer and/or metastasis in a subject using an adoptive T cell therapy, the method comprising administering to the subject a BRAF inhibitor (BRAFi) (such as, for example, sorafenib, vemurafenib, dabrafenib, and/or encorafenib) and an adoptive T cell therapy, wherein administration of the BRAF inhibitor increases insulin-like growth factor II receptor (IGF2R).

Abstract: Tumor infiltrating lymphocytes (TILs) are immune cells that have left the bloodstream and migrated into a tumor. TILs have been used in autologous adoptive transfer therapy for the treatment of cancer. Disclosed are methods for rapidly expanding tumor infiltrating lymphocytes using digested tumor cells.

Abstract: A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.

Abstract: A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.

Abstract: A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.